Sunshine Pharma Adds 16,000 Treasury Shares via HK$0.64 Million On-Market Buyback

Bulletin Express09-28

Sunshine Pharma (Sunshine Lake Pharma Co., Ltd.) disclosed that it repurchased 16,000 H-shares on 28 September 2026, spending HK$0.64 million at prices between HK$39.40 and HK$40.00 per share. The volume-weighted average cost was approximately HK$39.72.

Following the transaction, the company’s issued share capital (excluding treasury shares) fell by 0.005 % to 318.96 million shares, while treasury shares increased to 2.14 million. Total issued shares remained unchanged at 321.10 million.

The purchase was executed under the general mandate approved on 18 June 2026, which authorises buybacks of up to 57.60 million shares. Cumulative repurchases under this mandate now stand at 1.47 million shares, equivalent to 0.25 % of the shares outstanding on the mandate-approval date.

All 16,000 repurchased shares are being held in treasury; no shares have been cancelled. Under Hong Kong Stock Exchange rules, Sunshine Pharma is restricted from issuing new shares or transferring treasury shares until 27 October 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment